Purple Biotech Statistics
Total Valuation
Purple Biotech has a market cap or net worth of $11.52 million. The enterprise value is $975,733.
| Market Cap | 11.52M |
| Enterprise Value | 975,733 |
Important Dates
The next estimated earnings date is Tuesday, August 20, 2024, before market open.
| Earnings Date | Aug 20, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Purple Biotech has 31.17 million shares outstanding.
| Shares Outstanding | 31.17M |
| Owned by Insiders (%) | 3.80% |
| Owned by Institutions (%) | 9.53% |
| Float | 23.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.37 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.05 |
| EV / Sales | n/a |
| EV / EBITDA | 0.05 |
| EV / EBIT | 0.05 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.34, with a Debt / Equity ratio of 0.01.
| Current Ratio | 1.34 |
| Quick Ratio | n/a |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | n/a |
| Interest Coverage | 9.27 |
Financial Efficiency
Return on equity (ROE) is 51.30% and return on invested capital (ROIC) is -69.00%.
| Return on Equity (ROE) | 51.30% |
| Return on Assets (ROA) | 42.30% |
| Return on Capital (ROIC) | -69.00% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $938,200 |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.40% in the last 52 weeks. The beta is 0.49, so Purple Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | -73.40% |
| 50-Day Moving Average | 0.56 |
| 200-Day Moving Average | 0.81 |
| Relative Strength Index (RSI) | 31.20 |
| Average Volume (20 Days) | 562,222 |
Short Selling Information
| Short Interest | 274,028 |
| Short Previous Month | 309,868 |
| Short % of Shares Out | 6.95% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.64 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -21.62M |
| Pretax Income | 18.76M |
| Net Income | 18.76M |
| EBITDA | 21.23M |
| EBIT | 21.03M |
| Earnings Per Share (EPS) | -$0.79 |
Balance Sheet
The company has $10.85 million in cash and $307,000 in debt, giving a net cash position of $10.55 million or $0.34 per share.
| Cash & Cash Equivalents | 10.85M |
| Total Debt | 307,000 |
| Net Cash | 10.55M |
| Net Cash Per Share | $0.34 |
| Equity (Book Value) | 31.02M |
| Book Value Per Share | 1.00 |
| Working Capital | 2.89M |
Cash Flow
| Operating Cash Flow | -18.94M |
| Capital Expenditures | n/a |
| Free Cash Flow | -18.94M |
| FCF Per Share | -$0.75 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Purple Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -36.56% |
| Shareholder Yield | -36.56% |
| Earnings Yield | 162.84% |
| FCF Yield | -164.40% |
Analyst Forecast
The average price target for Purple Biotech is $9.67, which is 2,515.63% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.67 |
| Price Target Difference | 2,515.63% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on August 21, 2020. It was a reverse split with a ratio of 1:10.
| Last Split Date | Aug 21, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |